Home | Articles
Published on:October 2020
Indian Journal of Pharmaceutical Education and Research, 2020; 54(3s):s442-s456
Review Article | doi:10.5530/ijper.54.3s.143

Novel SARS-CoV-2 and COVID-2019 Outbreak: Current Perspectives on Plant-Based Antiviral Agents and Complementary Therapy


Authors and affiliation (s):

Sevgi Gezici1,2*, Nazim Sekeroglu2,3

1Department of Molecular Biology and Genetics, Faculty of Science and Literature, Kilis 7 Aralik University, Kilis, TURKEY.

2Advanced Technology Application and Research Center (ATARC), Kilis 7 Aralik University, Kilis, TURKEY.

3Department of Horticulture, Faculty of Agriculture, Kilis 7 Aralik University, 79000 Kilis-TURKEY.

Abstract:

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused the novel Corona Virus Disease 2019 (COVID-19), which has been defined as a pandemic by the World Health Organization (WHO) in 2020. The rapid global spread of SARS-CoV-2 virus as a global health emergency has emphasized to findeffective treatment strategies in clinical trials. The several drug trials including Lopinavir (LPV) and Ritonavir, Chloroquine (CLQ), Hydroxychloroquine, Favipiravir (FPV), Remdevisir (RDV), Nitazoxanide, Ivermectin and Interferon, have been explored in COVID-19 patients and some of the drugs have been waiting clinical approval for their anti-SARS-CoV-2 activities. Clinical trials are still ongoing to discover promising new multidrug combination treatment for COVID-19 patients. Considering the difficulties to ascertain efficient drug candidates and the lack of specific anti-viral therapies against COVID-19 outbreak, the current management of SARS-CoV-2 should mainly be supportive. From this point of view, enhancing the immune system through medicinal plants with wide range of bioactive compounds, which exhibit antiviral activities, can play significant roles to increase defense barrier in COVID-19 patients. On the other hand, plant-based agents as complementary and alternative therapies have potential advantages to reduce symptoms of this life-threatening disease and could promote the public health. Recently, there has been a remarkable progress in the field of antiviral herbal therapy owing to increasing concerns about the development of drug resistance and limited advances in the field of antiviral drug discovery. This review provides an overview of published information onbiology, genomic structure, replication cycle and pathogenesis of SARS-CoV-2. It also aims to assemble the fact and a scientific intellectual groundwork on development of antiviral herbal therapy on the bases of extensive literature collection.

Key words: SARS-CoV-2, COVID-19, Outbreak, Medicinal plants, Antiviral.

 




 

Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the 2019 Release of Journal Citation Reports (source: 2018 Web of Science Data).

 

Impact Factor® as reported in the 2018 Journal Citation Reports® (Clarivate Analytics, 2019): 0.425

User login

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs